Your source for biopharma news and jobs
Immunology-focused biotech Santa Ana Bio announced Thursday that it has launched with a $168 million war chest to advance two of its programs into the clinic next year designed to treat inflammatory
Analysts have raised their forecasts for the global weight-loss and obesity drug market, which they now expect to reach $150 billion by the early 2030s, according to an analysis by @Reuters published
AstraZeneca on Tuesday unveiled a roadmap for its business through the end of the decade, setting a lofty goal of achieving $80 billion in total revenue by 2030, up about 75% from $45.8 billion in
@AstraZeneca on Monday revealed plans to construct an end-to-end production facility in Singapore, designed to span the entire manufacturing process for its growing portfolio of antibody-drug
Novo Holdings announced Wednesday that it is buying a majority stake in the Austrian life sciences tools company Single Use Support, a provider of fluid management services. While Novo did not
Bayer released its first-quarter 2024 earnings on Tuesday announcing that it has reduced its headcount by approximately 1,500 jobs—mostly management positions—amid a slight decline in sales, while
Vertex Pharmaceuticals on Monday released its first-quarter 2024 earnings results, reporting a 13% year-over-year increase in product revenue driven by the continued growth of its cystic fibrosis
The March approval of ITF Therapeutics’ Duvyzat marked the third new FDA-approved treatment in 10 months for Duchenne muscular dystrophy (DMD), a genetic disorder that causes progressive muscle
Moderna has backed out of its gene editing deal with Metagenomi, handing back full global rights to the primary hyperoxaluria type 1 program and other related technologies, including base editors and
Novo Nordisk on Thursday announced first-quarter 2024 earnings including 24% year-over-year revenue growth, driven by the continued strong performance of its blockbuster type 2 diabetes therapy
@EliLillyandCo reported its first-quarter 2024 results on Tuesday including 26% year-over-year revenue growth driven by the strong performance of its type 2 diabetes treatment Mounjaro (tirzepatide)
The FDA on Thursday greenlit the use of Genentech’s Alecensa (alectinib) for the adjuvant treatment of patients with early-stage, anaplastic lymphoma kinase-positive non-small cell lung cancer who
